The Pancreas Center, Clinical Trials

Home > Patient Guide > Clinical Trials

Clinical Trials: Detail

Title:	Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients
Trial Start Date:	11/19/2007
Trial End Date:	11/18/2008
Principal Investigator:	Harold Frucht, MD
Description:	Up to 15% of pancreatic cancers have an inherited disease component. Several gene abnormalities and inherited cancer syndromes have been shown to increase the risk of developing pancreatic cancer, including the breast ovary cancer syndrome (BRCA mutations). Several studies have demonstrated that germline BRCA1 and BRCA2 mutations are associated with an increased risk of malignancies, including breast, ovarian and more recently pancreatic cancer. BRCA mutations are not common in the general population however, they are more common in the Ashkenazi Jewish population. Several mutations are present in Ashkenazi Jewish populations that modify cancer risk and treatment response which have been shown to interact directly with BRCA genes. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may allow early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
Criteria:	Inclusion criteria Pancreatic cancer patient at Columbia who are of Ashkenazi Jewish descent Exclusion criteria Unwillingness or inability to provide informed consent
URL:
Clinical Areas:	Pancreas
Contact:	For more information, please contact Joanna Martinez-Gomez, MPH Phone: 212-305-9337 E-mail: jm2648@columbia.edu

APPOINTMENT CENTER

What to expect from an appointment with a specialist:

Appointment Request Form
Directions to the Center